Neural cell adhesion molecule-positive peripheral T-cell lymphoma: a rare variant with a propensity for unusual sites of involvement [see comments]

Kern, W. F.; Spier, Catherine; Hanneman, EH; Miller, TP; Matzner, Monika; Grogan, TM

doi:10.1182/blood.v79.9.2432.bloodjournal7992432

Cited by 83 publications

(42 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In acute leukaemias, CD56 expression has been identified in approximately 13–23% of the cases (10). CD56 positivity is generally associated with cytogenetic abnormalities such as t(8;21), trisomy 8 in monocytic leukaemia (24,25). Because the CD56 antigen is a cell adhesion molecule, its expression on tumour cells is believed to play an important role in their localisation, and CD56 + leukaemias with involvement of unusual sites have been reported.…”

Section: Discussionmentioning

confidence: 99%

“…Because the CD56 antigen is a cell adhesion molecule, its expression on tumour cells is believed to play an important role in their localisation, and CD56 + leukaemias with involvement of unusual sites have been reported. In a recent review of extramedullary myeloid cell tumours, CD56 was described as a possible risk factor for extramedullary leukaemia (18,25,26).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The importance of CD7 and CD56 antigens in acute leukaemias

Tiftik

Bolaman

Batun

et al. 2004

International Journal of Clinical Practice

View full text Add to dashboard Cite

The prognostic significance of immunophenotypical properties of leukaemic cells is well known. However, the biological and clinical significance of CD7 and CD56 antigen expression in acute leukaemias are not clearly established. In patients with acute leukaemias, we identified CD7 and CD56 expression and analysed their associations with markers expressed early in haemopoietic ontogeny and clinical parameters. Among 22 patients with acute leukaemia [12 acute myeloblastic leukaemia (AML), 10 acute lymphoblastic leukaemia (ALL)], we found CD7 positivity in 15 of 22 patients (68%) and CD56 positivity in four patients (18%). CD7 positivity was observed in seven patients (58%) with AML and in eight patients (80%) with ALL. CD56 positivity was observed in three patients (25%) with AML and one patient (10%) with ALL. Lymphadenopathy was present in five patients and associated with hepatosplenomegaly in three patients with ALL. Splenomegaly and hepatomegaly were present in three patients with AML. Central nervous system involvement was seen in one patient with ALL. Complete remission was achieved in nine patients (41%) (five ALL and four AML). Our data showed that CD7 and CD56 positivity at diagnosis associated with low remission rate and biological aggressiveness in a significant proportion of patients. We suggest the evaluation of CD7 and CD56 in all patients with acute leukaemias at the time of diagnosis in view of poor clinical outcome.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

The importance of CD7 and CD56 antigens in acute leukaemias

Tiftik

Bolaman

Batun

et al. 2004

International Journal of Clinical Practice

View full text Add to dashboard Cite

show abstract

“…Very recently, Ichinohasama et sions 45 and are known to predominantly show an extranodal al 59 reported a case of LBL with note of the CD56, myeloid presentation with a broad morphologic spectrum. [5][6][7]11,[46][47][48][49][50] antigen, CD7 and cyCD3 expression, and germline configu-Such CD56 / lymphomas are prevalent in Asian populations, rations of TCR and Ig genes. The mediastinal mass without and an increasing number of reports have described nasal and nasal-type T/NK cell lymphomas, with pleomorphic/ polymorphous morphology, a frequent mucosal presentation a proclivity to involve the skin, lymph nodes, and bone Abbreviations: CHOP-B, cyclophosphamide, doxorubicin, vincristine, prednisolone, and bleomycin; DCMP, daunorubicin, cytosine arabinoside, 6-mercaptopurine, and prednisolone; CHOP-L, CHOP and L-asparaginase; LDCA, low-dose cytosine arbinoside; DCVP, daunorubicin, cytosine arabinoside, vindesine, and prednisolone; CR, complete remission; PR, partial response; NR, no response; PD, progressive disease; DOD, died of disease; allo BMT, allogeneic bone marrow transplantation; HLA, human leukocyte antigen; GVHD, graft-versus-host disease; LBL, lymphoblastic lymphoma; ACR, aclarubicin.…”

Section: Southern Blot Analysismentioning

confidence: 99%

“…Clinically, most of them responded lymphoid malignancies, mostly confined to those of T/NK to chemotherapeutic regimens for AML. However, in all, cell origin, [5][6][7][8] generally characterized by unique extranodal except for one case that died of graft-versus-host disease, involvement, with lesions in the nasal-paranasal region, skin, lung, and stomach, and often display the angiocentric growth pattern. Because the CD56 antigen has been found to corre-with a modification on fixation from 0.5% methanol-free formalderecurrence of leukemia occurred and they persued fatal clinihyde to 50% ethanol with 1% paraformaldehyde.…”

mentioning

confidence: 99%

CD7+ and CD56+ Myeloid/Natural Killer Cell Precursor Acute Leukemia: A Distinct Hematolymphoid Disease Entity

Suzuki

Yamamoto

Seto

et al. 1997

Blood

171

View full text Add to dashboard Cite

The disease spectrum of natural killer (NK) cell leukemias and lymphomas has recently been expanding with the continuing evolution in diagnostic concepts. We describe here seven cases of acute leukemia of conceivable myeloid and NK cell precursor phenotype in six men and one woman varying from 19 to 59 years of age (median, 46 years). Striking extramedullary involvement was evident at initial presentation, with peripheral lymphadenopathy and/or mediastinal masses. Two lacked any leukemic cells in the bone marrow at diagnosis. Using cytochemical myeloperoxidase staining, less than 3% of the leukemic cells showed positive reactivity. However, expression of CD7, CD33, CD34, CD56, and frequently HLA-DR, but not other NK, T-cell, and B-cell markers was observed. Cytoplasmic CD3 was detected in three of the cases by flow cytometry and in six by Northern blotting, suggesting an origin from common progenitors between the NK cell and myeloid lineages. All but one presented germline configurations of the T-cell receptor β and γ chain genes and Ig heavy chain gene. With regard to morphology, the cells were generally L2-shaped, with variation in cell size, round to moderately irregular nuclei and prominent nucleoli, pale cytoplasm, and a lack of azurophilic granules. Histopathologic examination of biopsied specimens of extramedullary tumors showed a lymphoblast-like morphology, implying the differential diagnostic problem from lymphoblastic lymphomas, especially in cases lacking bone marrow involvement. Three patients were successfully treated with chemotherapy for acute myeloid leukemia (AML), whereas three other patients proved refractory to chemotherapeutic regimens for lymphoid malignancies, although two responded to subsequent AML chemotherapy. However, despite intensive chemotherapy, including allogeneic bone marrow transplantation, most persued fatal courses within 41 months. These data suggested that the CD7+ and CD56+ myeloid/NK cell precursor acute leukemia might constitute a distinct biologic and clinical disease entity. Its recognition appears to be particularly important for the clinicopathologic evaluation of CD56+ hematolymphoid malignancies and the development of therapeutic approaches to such disease.

show abstract

“…Extranasal ENKTL was first described in 1992 by both Chan et al and Kern et al This entity shows many morphologic, immunophenotypic and genotypic similarities to nasal ENKTL. Compared with nasal ENKTL, the clinical and histopathologic features of cutaneous ENKTL are less defined.…”

mentioning

confidence: 99%